Historique
Éditeur OEDT / EMCDDA
Documents disponibles chez cet éditeur (517)
Ajouter le résultat à votre sélection Affiner la recherche
FRANÇAIS : Ce rapport de l'OEDT offre un tour d'horizon du phénomène de la toxicomanie en Europe : il fournit des renseignements sur les différents types de consommation, des données comparatives d'ordre épidémiologique ou encore des chiffres [...]
1999
RapportFRANÇAIS : Le quatrième rapport annuel de l'EMCDDA présente les données et statistiques comparées les plus récentes concernant les drogues et toxicomanies dans les Etats membres de l'Union Européenne. Après une présentation des traitements, de[...]
Cette première édition révèle que le problème de drogue dans ces pays diffère radicalement de la situation d'il y a cinq à sept ans. Traditionnellement considérés comme des pays de "transit", ils sont devenus aujourd'hui une cible pour ce qui co[...]
This publication presents the data and findings of the risk assessment on 1-(3-chlorophenyl)-2-(methylamino)propan-1-one (3-chloromethcathinone, 3-CMC), carried out by the extended Scientific Committee of the EMCDDA on 19 November 2021. On the b[...]
This publication presents the data and findings of the risk assessment on 2-(methylamino)-1-(3-methylphenyl)propan-1-one (3-methylmethcathinone, 3-MMC), carried out by the extended Scientific Committee of the EMCDDA on 18 November 2021. On the b[...]
This report presents the data and findings of the risk assessment on the new psychoactive substance, 4-methylamphetamine, that was conducted by the Scientific Committee of the EMCDDA. Concerns over the availability and use of this stimulant drug[...]
This report presents the data and findings of the risk assessment on the new psychoactive substance, 4-methylamphetamine, that was conducted by the Scientific Committee of the EMCDDA. Concerns over the availability and use of this stimulant drug[...]![4F-iBF. Report on the risk assessment of N-(4-fluorophenyl)-2-methyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide (4F-iBF) in the framework of the Council Decision on new psychoactive substances](https://bdoc.ofdt.fr/img_cache/pmb_ofdt_record_80448.webp)
This publication presents the data and findings of the risk assessment on N-(4-fluorophenyl)-2-methyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide (4F-iBF), carried out by the extended Scientific Committee of the EMCDDA on 7-8 November 2017. I[...]![4F-MDMB-BICA. Risk assessment report on a new psychoactive substance: methyl 2-{[1-(4-fluorobutyl)-1H-indole-3-carbonyl]amino}-3,3-dime-thylbutanoate (4F-MDMB-BICA) in accordance with Article 5c of Regulation (EC) No 1920/2006 (as amended)](https://bdoc.ofdt.fr/img_cache/pmb_ofdt_record_84048.webp)
This risk assessment report presents the summary findings and the conclusion of the risk assessment carried out by the Scientific Committee of the EMCDDA on 4F-MDMB-BICA. The report is intended for policymakers and decision-makers in the institu[...]
This report presents the data and findings of the risk assessment on the new psychoactive substance, 5-(2-aminopropyl)indole, that was conducted by the Scientific Committee of the EMCDDA. Concerns over the availability and use of this stimulant [...]![5F-MDMB-PINACA. Report on the risk assessment of methyl 2-{[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino}-3,3-dimethylbutanoate (5F-MDMB-PINACA) in the framework of the Council Decision on new psychoactive substances](https://bdoc.ofdt.fr/img_cache/pmb_ofdt_record_80447.webp)
This publication presents the data and findings of the risk assessment on methyl 2-{[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino}-3,3-dimethylbutanoate (5F-MDMB-PINACA), carried out by the extended Scientific Committee of the EMCDDA on 7-8 N[...]
This publication presents the data and findings of the risk assessment on N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA), carried out by the extended Scientific Committee of the EMCDDA on 7-8 No[...]
This publication presents the data and findings of the risk assessment on N-(1 phenethylpiperidin-4-yl)-N-phenylacrylamide (acryloylfentanyl), carried out by the extended Scientific Committee of the EMCDDA on 22 February 2017. On the basis of th[...]
This publication presents the data and findings of the risk assessment on N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (ADB-CHMINACA), carried out by the extended Scientific Committee of the EMCDDA on 7[...]
This report reviews developments in the neuroscience of addiction, explores how they might affect the way we view and treat drug problems, and considers the issues that they raise for drug policy in Europe. In language that is easily accessible,[...]
